Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.52 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158540 | 0.87 | PPARG (0.49) | ESR1ESR2PPARGPPARAPTGS2 | |
| SCHEMBL5272161 | 0.84 | PPARA (0.48) | ESR1ESR2PPARGPPARAACE | |
| SCHEMBL3535230 | 0.82 | ESR1 (0.58) | ESR1ESR2MIFMDM4MDM2 | |
| SCHEMBL3535227 | 0.82 | ESR1 (0.58) | ESR1ESR2MIFMDM4MDM2 | |
| SCHEMBL5892186 | 0.81 | PPARG (0.45) | PPARGPPARA | |
| SCHEMBL4343679 | 0.81 | PPARG (0.45) | PPARGPPARA | |
| SCHEMBL542969 | 0.80 | ESR1 (0.63) | ESR1ESR2MIFMDM4MDM2 | |
| SCHEMBL542970 | 0.80 | ESR1 (0.63) | ESR1ESR2MIFMDM4MDM2 | |
| SCHEMBL5024580 | 0.80 | ESR1 (0.63) | ESR1ESR2MIFMDM4MDM2 | |
| SCHEMBL5991961 | 0.79 | ESR1 (0.55) | ESR1ESR2MIFMDM4MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-0648212-B1 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS PHARMACEUTICAL | SMITHKLINE BEECHAM PLC (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1000938-A1 | Heterocyclic compounds as pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 2000-05-17 | — | — | EP | disclosed |
| US-6048883-A | HYPOGLYCEMIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-11 | — | — | US | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| US-5869495-A | TREATMENT AND/OR PROPHYLAXIS OF HYPERGLYCAEMIA | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-02-09 | — | — | US | disclosed |
| US-5827865-A | TREATMENT AND-OR PROPHYLAXIS OF HYPERGLYEMIA | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0648212-A1 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL | SMITHKLINE BEECHAM PLC (GB) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994001420-A1 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL | SMITHKLINE BEECHAM PLC (GB) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ESR1 2335/4885ESR2 1165/4885MIF 2463/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ESR1 2335/4885ESR2 1165/4885MIF 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.